Literature DB >> 15506935

Poly(ADP-ribose) polymerase inhibitors as potential chemotherapeutic agents.

H E Bryant1, T Helleday.   

Abstract

PARP [poly(ADP-ribose) polymerase] activity is up-regulated by binding to DNA strand breaks and its association with DNA repair is well documented. Many anticancer therapies work by inducing breaks in DNA, if unrepaired these can lead to cell death. As PARP promotes DNA repair there is a strong rational to suggest that its inhibition may increase the efficiency of certain cytotoxic treatments. This review discusses the advances made in PARP inhibitor design and the mechanism by which they enhance anti-tumour therapies.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15506935     DOI： 10.1042/BST0320959

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN： 0300-5127            Impact factor:   5.407


  13 in total

1.  Inhibition of PARP1-dependent end-joining contributes to Olaparib-mediated radiosensitization in tumor cells.

Authors:  Annika Kötter; Kerstin Cornils; Kerstin Borgmann; Jochen Dahm-Daphi; Cordula Petersen; Ekkehard Dikomey; Wael Y Mansour
Journal:  Mol Oncol       Date:  2014-07-01       Impact factor: 6.603

Review 2.  Susceptibility pathways in Fanconi's anemia and breast cancer.

Authors:  Alan D D'Andrea
Journal:  N Engl J Med       Date:  2010-05-20       Impact factor: 91.245

3.  Interaction of Sindbis virus non-structural protein 3 with poly(ADP-ribose) polymerase 1 in neuronal cells.

Authors:  Eunhye Park; Diane E Griffin
Journal:  J Gen Virol       Date:  2009-06-10       Impact factor: 3.891

4.  Recql5 plays an important role in DNA replication and cell survival after camptothecin treatment.

Authors:  Yiduo Hu; Xincheng Lu; Guangjin Zhou; Ellen L Barnes; Guangbin Luo
Journal:  Mol Biol Cell       Date:  2008-11-05       Impact factor: 4.138

Review 5.  Diseases associated with defective responses to DNA damage.

Authors:  Mark O'Driscoll
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-12-01       Impact factor: 10.005

Review 6.  Mechanisms of chemoresistance to alkylating agents in malignant glioma.

Authors:  Jann N Sarkaria; Gaspar J Kitange; C David James; Ruth Plummer; Hilary Calvert; Michael Weller; Wolfgang Wick
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

7.  Two small enzyme isoforms mediate mammalian mitochondrial poly(ADP-ribose) glycohydrolase (PARG) activity.

Authors:  Ralph G Meyer; Mirella L Meyer-Ficca; Clifford J Whatcott; Elaine L Jacobson; Myron K Jacobson
Journal:  Exp Cell Res       Date:  2007-04-19       Impact factor: 3.905

8.  Base excision repair targets for cancer therapy.

Authors:  Grigory L Dianov
Journal:  Am J Cancer Res       Date:  2011-08-12       Impact factor: 6.166

9.  PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?

Authors:  Joseph A De Soto; Chu-Xia Deng
Journal:  Int J Med Sci       Date:  2006-07-15       Impact factor: 3.738

10.  EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma.

Authors:  Lotte Hiddingh; Bakhos A Tannous; Jian Teng; Bas Tops; Judith Jeuken; Esther Hulleman; Sandra H Boots-Sprenger; W Peter Vandertop; David P Noske; Gertjan J L Kaspers; Pieter Wesseling; Thomas Wurdinger
Journal:  Oncotarget       Date:  2014-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.